Literature DB >> 23584883

Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease.

Hirofumi Yano1, Yoshifuru Tamura, Kana Kobayashi, Masayuki Tanemoto, Shunya Uchida.   

Abstract

BACKGROUND: Uric acid (UA) remains a risk factor of chronic kidney disease (CKD). Therefore, it is important to clarify the mechanism of UA excretion in CKD. The specific mechanisms of extrarenal excretion from the intestine are unknown. We evaluated the expression of the UA transporter in the intestinal tract--the ATP-binding cassette transporter G2 (ABCG2)--in a 5/6 nephrectomy rat model of CKD.
METHODS: Male Wistar rats (6 weeks old) were randomly assigned to the 5/6 nephrectomized (Nx) group or the sham-operated control group. Urine and blood samples were collected every 4 weeks. All the rats were killed at 8 weeks to obtain liver, duodenum, jejunum, ileum, and transverse colon tissues. Uricase activity was measured in the liver. Expression of ABCG2 in intestinal mucosa was measured with real time polymerase chain reaction (PCR).
RESULTS: The Nx group showed significantly decreased urine UA excretion/body weight and UA clearance compared to the control group at 4 and 8 weeks after nephrectomy. In contrast, serum UA and uricase activity were not significant. The expression of ABCG2 in the ileum of the Nx group showed significantly increased upregulation, while no changes were seen in the intestines of the control group.
CONCLUSIONS: The Nx rats exhibited lower excretion of urine UA and over-expression of ABCG2 in the ileum. The fact that serum UA did not increase despite the decrease in UA excretion suggests that an excretory pathway other than the kidney, probably the intestine, may operate in a complementary role that corroborates the increase in ABCG2 expression in the ileum.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23584883     DOI: 10.1007/s10157-013-0806-8

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  27 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Origin and extrarenal elimination of uric acid in man.

Authors:  L B Sorensen; D J Levinson
Journal:  Nephron       Date:  1975       Impact factor: 2.847

3.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

Authors:  M Maliepaard; G L Scheffer; I F Faneyte; M A van Gastelen; A C Pijnenborg; A H Schinkel; M J van De Vijver; R J Scheper; J H Schellens
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.

Authors:  Hirotaka Matsuo; Tappei Takada; Kimiyoshi Ichida; Takahiro Nakamura; Akiyoshi Nakayama; Yuki Ikebuchi; Kousei Ito; Yasuyoshi Kusanagi; Toshinori Chiba; Shin Tadokoro; Yuzo Takada; Yuji Oikawa; Hiroki Inoue; Koji Suzuki; Rieko Okada; Junichiro Nishiyama; Hideharu Domoto; Satoru Watanabe; Masanori Fujita; Yuji Morimoto; Mariko Naito; Kazuko Nishio; Asahi Hishida; Kenji Wakai; Yatami Asai; Kazuki Niwa; Keiko Kamakura; Shigeaki Nonoyama; Yutaka Sakurai; Tatsuo Hosoya; Yoshikatsu Kanai; Hiroshi Suzuki; Nobuyuki Hamajima; Nariyoshi Shinomiya
Journal:  Sci Transl Med       Date:  2009-11-04       Impact factor: 17.956

5.  Molecular identification of a renal urate anion exchanger that regulates blood urate levels.

Authors:  Atsushi Enomoto; Hiroaki Kimura; Arthit Chairoungdua; Yasuhiro Shigeta; Promsuk Jutabha; Seok Ho Cha; Makoto Hosoyamada; Michio Takeda; Takashi Sekine; Takashi Igarashi; Hirotaka Matsuo; Yuichi Kikuchi; Takashi Oda; Kimiyoshi Ichida; Tatsuo Hosoya; Kaoru Shimokata; Toshimitsu Niwa; Yoshikatsu Kanai; Hitoshi Endou
Journal:  Nature       Date:  2002-04-14       Impact factor: 49.962

6.  High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.

Authors:  Linda H Ficociello; Elizabeth T Rosolowsky; Monika A Niewczas; Nicholas J Maselli; Janice M Weinberg; Ann Aschengrau; John H Eckfeldt; Robert C Stanton; Andrzej T Galecki; Alessandro Doria; James H Warram; Andrzej S Krolewski
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

7.  Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.

Authors:  Naohiko Anzai; Kimiyoshi Ichida; Promsuk Jutabha; Toru Kimura; Ellappan Babu; Chun Ji Jin; Sunena Srivastava; Kenichiro Kitamura; Ichiro Hisatome; Hitoshi Endou; Hiroyuki Sakurai
Journal:  J Biol Chem       Date:  2008-08-13       Impact factor: 5.157

Review 8.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).

Authors:  L Austin Doyle; Douglas D Ross
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

9.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.

Authors:  Owen M Woodward; Anna Köttgen; Josef Coresh; Eric Boerwinkle; William B Guggino; Michael Köttgen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-08       Impact factor: 11.205

Review 10.  The role of hyperuricemia in vascular disorders.

Authors:  N Lawrence Edwards
Journal:  Curr Opin Rheumatol       Date:  2009-03       Impact factor: 5.006

View more
  35 in total

Review 1.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

Review 2.  The effect of polymorphism of uric acid transporters on uric acid transport.

Authors:  Ze Wang; Tao Cui; Xiaoyan Ci; Fang Zhao; Yinghui Sun; Yazhuo Li; Rui Liu; Weidang Wu; Xiulin Yi; Changxiao Liu
Journal:  J Nephrol       Date:  2018-10-31       Impact factor: 3.902

Review 3.  The systems biology of uric acid transporters: the role of remote sensing and signaling.

Authors:  Sanjay K Nigam; Vibha Bhatnagar
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-07       Impact factor: 2.894

Review 4.  Hyperuricemia and Hypertension: Links and Risks.

Authors:  Douglas J Stewart; Valerie Langlois; Damien Noone
Journal:  Integr Blood Press Control       Date:  2019-12-24

Review 5.  What do drug transporters really do?

Authors:  Sanjay K Nigam
Journal:  Nat Rev Drug Discov       Date:  2014-12-05       Impact factor: 84.694

Review 6.  Linking uric acid metabolism to diabetic complications.

Authors:  Akifumi Kushiyama; Kentaro Tanaka; Shigeko Hara; Shoji Kawazu
Journal:  World J Diabetes       Date:  2014-12-15

Review 7.  Time to target uric acid to retard CKD progression.

Authors:  Takanori Kumagai; Tatsuru Ota; Yoshifuru Tamura; Wen Xiu Chang; Shigeru Shibata; Shunya Uchida
Journal:  Clin Exp Nephrol       Date:  2016-06-23       Impact factor: 2.801

Review 8.  Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling.

Authors:  Sanjay K Nigam; Kevin T Bush
Journal:  Nat Rev Nephrol       Date:  2019-05       Impact factor: 28.314

9.  CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.

Authors:  Ze-An Zhao; Yu Jiang; Yan-Yu Chen; Ting Wu; Qun-Sheng Lan; Yong-Mei Li; Lu Li; Yang Yang; Cui-Ting Lin; Ying Cao; Ping-Zheng Zhou; Jia-Yin Guo; Yuan-Xin Tian; Jian-Xin Pang
Journal:  Acta Pharmacol Sin       Date:  2021-03-25       Impact factor: 6.150

Review 10.  Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination.

Authors:  Jinghui Zhang; Haoxun Wang; Yunzhou Fan; Zhou Yu; Guofeng You
Journal:  Pharmacol Ther       Date:  2020-08-03       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.